Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 1 September 2017

Verona Pharma Appoints Stifel as Nominated Adviser

Verona Pharma plc    

Published: 08:00 CEST 01-09-2017 /GlobeNewswire /Source: Verona Pharma plc / : VRP /ISIN: GB00BYW2KH80

Verona Pharma Appoints Stifel as Nominated Adviser

LONDON, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to announce the appointment of Stifel Nicolaus Europe Limited as its Nominated Adviser and Sole Broker with immediate effect.

 

About Verona Pharma plc

 

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

 

Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.

 

 

For further information, please contact:

 

Verona Pharma plc

Tel: +44 (0)20 3283 4200

Jan-Anders Karlsson, Chief Executive Officer

info@veronapharma.com

 

 

Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)

Tel: +44 (0)20 7710 7600

Stewart Wallace / Jonathan Senior / Ben Maddison

SNELVeronaPharma@stifel.com

 

 

ICR, Inc. (US Media and Investor Enquiries)

 

Darcie Robinson

Tel: +1 203 682 8379

 

Darcie.Robinson@icrinc.com

Stephanie Carrington

Tel: +1 646 277 1282

 

Stephanie.Carrington@icrinc.com

 

 

FTI Consulting (UK Media and Investor Enquiries)

Tel: +44 (0)20 3727 1000

Simon Conway / Stephanie Cuthbert /

Natalie Garland-Collins

veronapharma@fticonsulting.com

 





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Verona Pharma plc, 3 More London Riverside, London SE1 2RE, United Kingdom
If you would like to unsubscribe and stop receiving these e-mails click here.